A Phase 3 Randomized, Double Blind, Multi-National Evaluation of Daclatasvir in Combination With Peg Interferon Alfa-2a and Ribavirin in Treatment-Naive Subjects With Chronic Hepatitis C Genotypes 1 and 4
Status: Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 21 Nov 2013
Price : $35 *
At a glance
- Drugs Daclatasvir (Primary) ; Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms COMMAND-Asia
- 21 Nov 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 17 Jul 2013 Planned number of patients changed from 885 to 890 as reported by ClinicalTrials.gov record.
- 17 Jul 2013 Planned end date changed from 1 Oct 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov record.